Flemington, NJ, United States of America

Kevin Joseph Klopfer

USPTO Granted Patents = 18 (Patent Applications = 4)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 3.4

ph-index = 2

Forward Citations = 33(Granted Patents)

Company Filing History:

Signal Pharmaceuticals, Inc.

Years Active: 2007-2025

Loading Chart...

18 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12215094 - Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol (2025-02-04),

2. 11406629 - Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereof (2022-08-09),

3. 10835522 - Solid forms comprising 4-amino-2-(2,6- dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereof (2020-11-17),

4. 10376503 - Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereof (2019-08-13),

5. 10052323 - Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use (2018-08-21),

6. 9974786 - [object Object] (2018-05-22),

7. 9974780 - Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereof (2018-05-22),

8. 9968627 - Solid forms comprising 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereof (2018-05-15),

9. 9808450 - Solid forms comprising 3-(4-amino-1-OXO-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof (2017-11-07),

10. 9795603 - Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use (2017-10-24),

11. 9718824 - Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof (2017-08-01),

12. 9695146 - Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereof (2017-07-04),

13. 9604939 - Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use (2017-03-28),

14. 9403829 - [object Object] (2016-08-02),

15. 9085551 - Solid forms of 3-(4-nitro-1-oxisoindolin-2-yl)piperidine-2,6-dione (2015-07-21),

Title: Kevin Joseph Klopfer: A Pioneer in Pharmaceutical Innovations

Introduction

Kevin Joseph Klopfer, an accomplished inventor based in Flemington, NJ, has made significant contributions to the field of pharmaceuticals. With an impressive portfolio of 18 patents, Klopfer is known for his expertise in developing solid forms of complex chemical compounds that have the potential to improve medical treatments.

Latest Patents

Among his most recent innovations are patents that focus on the creation of solid forms for various pharmaceutical compounds. One such patent involves solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl] amino}-1,3,5-triazin-2-yl) amino]propan-2-ol, describing methods of making and utilizing these solid forms. Another notable patent features solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione coupled with a coformer. This invention also covers pharmaceutical compositions and methods for managing various medical disorders.

Career Highlights

Throughout his career, Kevin Klopfer has worked with renowned organizations such as Celgene Corporation and Signal Pharmaceuticals, Inc. His work has contributed to advancements in the pharmaceutical industry, particularly in the area of drug formulation and delivery.

Collaborations

Collaboration has been a vital aspect of Klopfer's success. He has partnered with talented individuals, including coworkers Ho-Wah Hui and G. Patrick Stahly, to further innovate in the realm of pharmaceutical development. Their collective expertise has led to breakthroughs that significantly enhance the efficacy and safety of new drug compounds.

Conclusion

Kevin Joseph Klopfer stands as a prominent figure in the landscape of pharmaceutical innovation. With 18 patents to his name and a history of collaboration with other skilled professionals, his work continues to influence the field, potentially improving treatment options for various medical conditions. His contributions emphasize the importance of ongoing research and development in creating safer and more effective pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.